HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.

Abstract
Current guidelines recommend troponin T (TnT) as the biomarker of choice in the diagnosis of myocardial infarction. In patients with ST-elevation myocardial infarction (STEMI) however, its role in providing a measurement of infarct size and its association with survival is less well established. We sought to assess the correlation of TnT and creatine kinase-MB (CK-MB) with scintigraphically determined infarct size and to assess the predictive value of all 3 parameters on 12-month mortality. Patients presenting with STEMI managed with primary percutaneous intervention underwent serial TnT and CK-MB measurements at admission and for ≥72 hours after presentation. Before hospital discharge patients underwent assessment of infarct size by technetium-99m sestamibi single-photon emission computed tomographic (SPECT) scan. Clinical follow-up was performed up to 1 year. Data were available for 1,237 patients. Mean age was 62.9 ± 12.9 years. Infarct location was anterior in 509 patients (41%); 75 (6.1%) had cardiogenic shock. Median admission and peak TnT were 0.74 μg/L (0.10 to 2.70) and 3.70 μg/L (1.69 to 6.99), respectively. Corresponding values for CK-MB were 44.1 U/L (21.0 to 108.8) and 160.0 U/L (69.0 to 301.0), respectively. Median infarct size on SPECT scan was 12.0% (3.0 to 25.0) of the left ventricle. Peak TnT and CK-MB demonstrated similar moderate correlation with final infarct size (r = 0.45, p <0.001, and r = 0.41, p <0.001 respectively). This correlation was not affected by Thrombolysis In Myocardial Infarction flow grade after intervention. At 1 year, 47 patients (3.8%) had died. Final infarct size at SPECT scanning better predicted mortality than peak TnT or CK-MB. In conclusion, this study is the largest investigation on the value of cardiac troponin for assessment of infarct size in acute STEMI. Compared to peak CK-MB, peak TnT shows similar correlation with scintigraphic infarct size, although scintigraphic infarct size remains a better correlate of 1-year mortality than either biomarker.
AuthorsRobert A Byrne, Gjin Ndrepepa, Siegmund Braun, Klaus Tiroch, Julinda Mehilli, Stefanie Schulz, Albert Schömig, Adnan Kastrati
JournalThe American journal of cardiology (Am J Cardiol) Vol. 106 Issue 9 Pg. 1212-7 (Nov 01 2010) ISSN: 1879-1913 [Electronic] United States
PMID21029815 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Platelet Aggregation Inhibitors
  • Radiopharmaceuticals
  • Troponin T
  • Technetium Tc 99m Sestamibi
  • Clopidogrel
  • Creatine Kinase, MB Form
  • Ticlopidine
  • Aspirin
Topics
  • Angioplasty, Balloon, Coronary
  • Aspirin (therapeutic use)
  • Biomarkers (blood)
  • Clopidogrel
  • Combined Modality Therapy
  • Creatine Kinase, MB Form (blood)
  • Female
  • Germany (epidemiology)
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (blood, diagnostic imaging, mortality, pathology, therapy)
  • Myocardial Perfusion Imaging
  • Platelet Aggregation Inhibitors
  • Prognosis
  • Prospective Studies
  • Radiopharmaceuticals
  • Registries
  • Technetium Tc 99m Sestamibi
  • Ticlopidine (analogs & derivatives, therapeutic use)
  • Tomography, Emission-Computed, Single-Photon
  • Troponin T (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: